- Home
- BANF vs RCUS Comparison
BANF vs RCUS Comparison
Compare BANF & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANF | RCUS |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | 2260 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BANF | RCUS |
|---|---|---|
| Price | $116.33 | $27.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $124.00 | $31.90 |
| AVG Volume (30 Days) | 196.7K | ★ 1.5M |
| Earning Date | 04-16-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $3.92 | $45.62 |
| P/E Ratio | $16.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $101.48 | $8.84 |
| 52 Week High | $138.15 | $31.74 |
Technical Indicators
Market Signals| Indicator | BANF | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 48.46 |
| Support Level | $110.33 | $20.20 |
| Resistance Level | $122.05 | $28.72 |
| Average True Range (ATR) | 2.47 | 1.37 |
| MACD | 0.40 | -0.48 |
| Stochastic Oscillator | 56.11 | 28.74 |
Price Performance
Historical ComparisonAbout BANF BancFirst Corporation
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.